ANTERIS TECHNOLOGIES GLOBAL
AVRNASDAQTrading Snapshot
- Day Range
- $5.95 β $6.18
- 52-Week Range
- $3.30 β $11.06
- Volume (shares)
- 122,708
- Avg Volume (shares)
- β
- Shares Outstanding
- 97.5M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $1M
- P/E Ratio
- -2.2
- P/S Ratio
- 265.2x
- EPS (TTM)
- $-1.06
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.0%
ANTERIS TECHNOLOGIES GLOBAL
AVRAbout ANTERIS TECHNOLOGIES GLOBAL
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates
News unavailable.